Skip to main content

Table 6 Logistic regression analysis to identify patients harboring the T790M substitution upon rebiopsy (n = 89)

From: Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Variables Univariate Analyses Multivariate Analysis
OR 95%CI P-value OR 95%CI P-value
Original mutation; absent vs. present 30.5 8.05–115.3 <  0.001 41.5 6.53–264.3 <  0.001
Type of Biopsy; Liquid vs. Tissue 14.6 5.04–42.6 <  0.001 NI
Detection of New tumor lesion; <  4 vs 4 ≤ 5.67 2.24–14.4 <  0.001 NI
Number of Tissue biopsy 5.72 2.30–14.2 <  0.001 NI
Detection of New metastatic organ; 0 → 4 2.35 1.39–3.97 0.001 NI
Number of tumor lesion; <  6 vs 6 ≤ 5.61 2.0–15.7 0.001 NI
Brain metastases; absent vs. present 4.40 1.71–11.3 0.002 27.8 3.13–247.8 0.003
Bone metastases; absent vs. present 3.94 1.55–9.98 0.004 NI
Number of Liquid biopsy 0.69 0.52–0.90 0.006 NI
Enlargement of Tumor size; <  12 mm vs 12 mm ≤ 3.47 1.42–8.49 0.007 24.5 2.65–226.7 0.005
New brain metastases; absent vs. present 4.5 1.26–16.1 0.02 NI
Mutation site at initial diagnosis; Exon19 Deletion vs. L858R 3.08 1.06–8.95 0.04 3.90 0.63–24.3 0.145
Minor site metastases; absent vs. present 4.20 1.07–16.5 0.04 21.3 1.40–325.6 0.03
New hepatic metastases; absent vs. present 3.64 0.85–15.7 0.08 NI
New minor site metastases; absent vs. present 4.48 0.82–24.6 0.08 NI
Hepatic metastases; absent vs. present 2.54 0.99–1.09 0.141 NI
  1. Abbreviations: OR Odds ratio; CI confidence interval; Variables with a p-value < 0.15 on univariate analysis were entered into multivariate logistical analysis by a simultaneous method. NI not included in the best multivariate logistic regression model
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us